Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM)

Corcept Therapeutics

Status: Completed

Conditions: Cushing's Syndrome

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02663609

C1073-450

Details and patient eligibility

About

Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.

Full description

A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.

Enrollment: 24 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with ACTH independent endogenous Cushing's Syndrome
• Available adrenal imaging prior to being treated with Korlym®
• Treated with Korlym® and followed for at least 3 months (follow-up data should be available)

Exclusion criteria

• Diagnosed with adrenocortical carcinoma
• Participant in any clinical trial(s) during the observational period